Gene Therapy Program

Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1)

Severe combined immunodeficiency (SCID), often referred to as “bubble boy disease,” is a rare hereditary condition that makes infants vulnerable to infection. Essentially, children with SCID lack an immune system.

SCID is caused by genetic mutations. In the most common form of the disease, X-linked SCID (SCID-X1), the gene responsible is IL2RG, which is needed for the healthy development of several kinds of immune cells — T and natural killer lymphocytes and nonfunctional B lymphocytes. The current treatment for SCID-X1 is a bone marrow transplant that can produce normal immune cells, but finding a suitable can be a challenge.

How gene therapy for SCID-X1 works

To perform SCID-X1 gene therapy, a patient’s blood stem cells (these are the cells that give rise to all mature blood stem cells) are collected. In a highly-specialized laboratory, a viral vector is used as a carrier to insert a correct version of the faulty IL2RG gene into the patient’s stem cells. Then, the patient receives chemotherapy to make room for the genetically-altered cells. Finally, the cells are given back to the patient via an intravenous infusion.

Gallagher family whose son, Paul, underwent SCID gene therapy

Meet Paul.

Parents La Dreama Wood and Kevin Gallagher were preparing for their first baby together when they learned he would be born with SCID. They would have to make a choice between two treatments: a bone marrow transplant or a gene therapy clinical trial. In their own words, learn about their decision and their journey.


SCID-X1 gene therapy clinical trial

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Recruiting males up to 5 Years (full eligibility criteria)
Boston Children’s Hospital

Started: Jan. 2018

Sung-Yun Pai, MD, principal investigator
Colleen Dansereau, MSN, RN, CPN617-919-7008 or

Dana-Farber Boston Children's Cancer and Blood Disorders Center logo

We are proud to serve a broad and diverse patient population that often comes to us for answers they can't find anywhere else. This top ranking is a credit and a tribute to our extraordinary and deeply committed clinicians, researchers and so many others who dedicate every day to improving and advancing the health and well-being of all children.

Sandra L. Fenwick, CEO

Connect with Boston Children's Hospital